Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 13.63
UTHR's Cash to Debt is ranked lower than
56% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. UTHR: 13.63 )
Ranked among companies with meaningful Cash to Debt only.
UTHR' s 10-Year Cash to Debt Range
Min: 0.69  Med: 5.70 Max: 15951.56
Current: 13.63
0.69
15951.56
Equity to Asset 0.60
UTHR's Equity to Asset is ranked lower than
60% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. UTHR: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
UTHR' s 10-Year Equity to Asset Range
Min: 0.37  Med: 0.66 Max: 0.97
Current: 0.6
0.37
0.97
Interest Coverage 30.63
UTHR's Interest Coverage is ranked lower than
86% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 30.63 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s 10-Year Interest Coverage Range
Min: 2.02  Med: 20.77 Max: 3302.25
Current: 30.63
2.02
3302.25
F-Score: 8
Z-Score: 9.12
M-Score: -3.56
WACC vs ROIC
2.36%
25.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.44
UTHR's Operating margin (%) is ranked higher than
87% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. UTHR: 22.44 )
Ranked among companies with meaningful Operating margin (%) only.
UTHR' s 10-Year Operating margin (%) Range
Min: -24714.81  Med: 7.03 Max: 46.03
Current: 22.44
-24714.81
46.03
Net-margin (%) 12.83
UTHR's Net-margin (%) is ranked higher than
81% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. UTHR: 12.83 )
Ranked among companies with meaningful Net-margin (%) only.
UTHR' s 10-Year Net-margin (%) Range
Min: -23703.7  Med: 9.41 Max: 56.09
Current: 12.83
-23703.7
56.09
ROE (%) 15.12
UTHR's ROE (%) is ranked higher than
88% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. UTHR: 15.12 )
Ranked among companies with meaningful ROE (%) only.
UTHR' s 10-Year ROE (%) Range
Min: -95.31  Med: 8.27 Max: 30.84
Current: 15.12
-95.31
30.84
ROA (%) 9.08
UTHR's ROA (%) is ranked higher than
88% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. UTHR: 9.08 )
Ranked among companies with meaningful ROA (%) only.
UTHR' s 10-Year ROA (%) Range
Min: -85.24  Med: 5.86 Max: 26.08
Current: 9.08
-85.24
26.08
ROC (Joel Greenblatt) (%) 62.88
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. UTHR: 62.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1861.26  Med: 37.33 Max: 118.55
Current: 62.88
-1861.26
118.55
Revenue Growth (3Y)(%) 23.90
UTHR's Revenue Growth (3Y)(%) is ranked higher than
81% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. UTHR: 23.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
UTHR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 37.85 Max: 231.7
Current: 23.9
0
231.7
EBITDA Growth (3Y)(%) 22.80
UTHR's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. UTHR: 22.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
UTHR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56  Med: 8.80 Max: 127.7
Current: 22.8
-56
127.7
EPS Growth (3Y)(%) 19.70
UTHR's EPS Growth (3Y)(%) is ranked higher than
79% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. UTHR: 19.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
UTHR' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4  Med: 10.10 Max: 153.6
Current: 19.7
-50.4
153.6
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

UTHR Guru Trades in Q3 2014

Steven Cohen 8,700 sh (New)
First Eagle Investment 262,080 sh (New)
Joel Greenblatt 288,401 sh (-55.36%)
John Hussman 50,000 sh (-62.69%)
Paul Tudor Jones 3,019 sh (-63.04%)
Jim Simons 2,378 sh (-99.06%)
» More
Q4 2014

UTHR Guru Trades in Q4 2014

Jim Simons 185,238 sh (+7689.66%)
First Eagle Investment 360,180 sh (+37.43%)
Joel Greenblatt 323,088 sh (+12.03%)
John Hussman 50,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 2,400 sh (-20.50%)
» More
Q1 2015

UTHR Guru Trades in Q1 2015

Lee Ainslie 4,500 sh (New)
Ken Fisher 2,450 sh (New)
Louis Moore Bacon 6,000 sh (New)
Jim Simons 446,500 sh (+141.04%)
First Eagle Investment 372,580 sh (+3.44%)
Joel Greenblatt 291,077 sh (-9.91%)
Paul Tudor Jones 1,800 sh (-25.00%)
John Hussman 25,000 sh (-50.00%)
» More
Q2 2015

UTHR Guru Trades in Q2 2015

John Hussman 25,000 sh (unchged)
Ken Fisher 2,450 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 132.80
UTHR's P/E(ttm) is ranked lower than
82% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. UTHR: 132.80 )
Ranked among companies with meaningful P/E(ttm) only.
UTHR' s 10-Year P/E(ttm) Range
Min: 8.83  Med: 27.96 Max: 218.78
Current: 132.8
8.83
218.78
Forward P/E 12.02
UTHR's Forward P/E is ranked higher than
83% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. UTHR: 12.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 132.30
UTHR's PE(NRI) is ranked lower than
83% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. UTHR: 132.30 )
Ranked among companies with meaningful PE(NRI) only.
UTHR' s 10-Year PE(NRI) Range
Min: 8.84  Med: 27.79 Max: 227.53
Current: 132.3
8.84
227.53
P/B 7.55
UTHR's P/B is ranked lower than
67% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. UTHR: 7.55 )
Ranked among companies with meaningful P/B only.
UTHR' s 10-Year P/B Range
Min: 2.01  Med: 4.30 Max: 10.39
Current: 7.55
2.01
10.39
P/S 6.06
UTHR's P/S is ranked higher than
68% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. UTHR: 6.06 )
Ranked among companies with meaningful P/S only.
UTHR' s 10-Year P/S Range
Min: 2.83  Med: 6.73 Max: 18.02
Current: 6.06
2.83
18.02
PFCF 19.20
UTHR's PFCF is ranked higher than
77% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. UTHR: 19.20 )
Ranked among companies with meaningful PFCF only.
UTHR' s 10-Year PFCF Range
Min: 9.7  Med: 25.50 Max: 666.33
Current: 19.2
9.7
666.33
POCF 18.19
UTHR's POCF is ranked higher than
76% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. UTHR: 18.19 )
Ranked among companies with meaningful POCF only.
UTHR' s 10-Year POCF Range
Min: 8.25  Med: 22.24 Max: 189.61
Current: 18.19
8.25
189.61
EV-to-EBIT 24.44
UTHR's EV-to-EBIT is ranked higher than
63% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. UTHR: 24.44 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s 10-Year EV-to-EBIT Range
Min: -29.2  Med: 21.00 Max: 363.2
Current: 24.44
-29.2
363.2
PEG 2.37
UTHR's PEG is ranked higher than
56% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.73 vs. UTHR: 2.37 )
Ranked among companies with meaningful PEG only.
UTHR' s 10-Year PEG Range
Min: 0.49  Med: 0.74 Max: 7.22
Current: 2.37
0.49
7.22
Shiller P/E 48.36
UTHR's Shiller P/E is ranked lower than
51% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.33 vs. UTHR: 48.36 )
Ranked among companies with meaningful Shiller P/E only.
UTHR' s 10-Year Shiller P/E Range
Min: 24.86  Med: 64.38 Max: 129.35
Current: 48.36
24.86
129.35
Current Ratio 1.53
UTHR's Current Ratio is ranked lower than
80% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. UTHR: 1.53 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s 10-Year Current Ratio Range
Min: 0.96  Med: 7.00 Max: 64.22
Current: 1.53
0.96
64.22
Quick Ratio 1.39
UTHR's Quick Ratio is ranked lower than
78% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. UTHR: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s 10-Year Quick Ratio Range
Min: 0.9  Med: 6.47 Max: 64.22
Current: 1.39
0.9
64.22
Days Inventory 264.42
UTHR's Days Inventory is ranked lower than
83% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. UTHR: 264.42 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s 10-Year Days Inventory Range
Min: 118.32  Med: 207.07 Max: 518.99
Current: 264.42
118.32
518.99
Days Sales Outstanding 45.72
UTHR's Days Sales Outstanding is ranked higher than
66% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. UTHR: 45.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s 10-Year Days Sales Outstanding Range
Min: 36.71  Med: 49.96 Max: 675.93
Current: 45.72
36.71
675.93

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.76
UTHR's Price/Tangible Book is ranked lower than
61% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. UTHR: 7.76 )
Ranked among companies with meaningful Price/Tangible Book only.
UTHR' s 10-Year Price/Tangible Book Range
Min: 1.16  Med: 3.79 Max: 18.18
Current: 7.76
1.16
18.18
Earnings Yield (Greenblatt) (%) 4.10
UTHR's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. UTHR: 4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
UTHR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 3.85 Max: 18
Current: 4.1
0.3
18
Forward Rate of Return (Yacktman) (%) 23.92
UTHR's Forward Rate of Return (Yacktman) (%) is ranked higher than
70% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.59 vs. UTHR: 23.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
UTHR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -3.6  Med: 0.70 Max: 56.9
Current: 23.92
-3.6
56.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered subcutaneously (under the skin) or intravenously (in the vein) for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor. PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cyclic GMP) in cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health (NIH). Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung Transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products including the following: Flolan, Ventavis, Ilomedin , Tracleer, Revatio, Letairis , Veletri, Adempas, Opsumit , generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
FDA Approval Of Cancer Drug Catapults United Therapeutics Shares By 2% Mar 11 2015 
Weekly CFO Sells Highlight: United Therapeutics Corp, Williams Companies Inc, Facebook Inc. Oct 12 2014 
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
John Hussman's Third Quarter Top 5 Nov 07 2013 
Vanguard Health Care Fund Selling Update Oct 30 2013 
comment on UTHR May 11 2013 
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 
comment on UTHR Mar 23 2013 

More From Other Websites
UNITED THERAPEUTICS CORP Financials Jul 31 2015
United Therapeutics Misses on Q2 Earnings & Revenues - Analyst Blog Jul 29 2015
United Therapeutics (UTHR) Earnings Report: Q2 2015 Conference Call Transcript Jul 28 2015
4 IBD 50 Stocks Poised To Bounce Back With Market Jul 28 2015
Edited Transcript of UTHR earnings conference call or presentation 28-Jul-15 1:00pm GMT Jul 28 2015
5 Health Care Stocks to Trade for Gains -- Must-See Charts Jul 28 2015
United Therapeutics Plunges On Q2 Sales Miss Jul 28 2015
Q2 2015 United Therapeutics Corp Earnings Release - Before Market Open Jul 28 2015
United Therapeutics Corporation Reports Second Quarter 2015 Financial Results Jul 28 2015
United Therapeutics beats 2Q profit forecasts Jul 28 2015
United Therapeutics beats 2Q profit forecasts Jul 28 2015
UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition Jul 28 2015
UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report Jul 28 2015
United Therapeutics Corporation Reports Second Quarter 2015 Financial Results Jul 28 2015
United Therapeutics Corporation To Announce Second Quarter 2015 Financial Results Before Market Open... Jul 22 2015
United Therapeutics Corporation To Announce Second Quarter 2015 Financial Results Before Market Open... Jul 22 2015
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History Jul 21 2015
Mayo Clinic and United Therapeutics Collaborate on Lung Restoration Center Jul 13 2015
Why Jazz Pharmaceuticals Is Winning Jun 29 2015
Dean Judy D. Olian Joins the United Therapeutics Corporation Board of Directors Jun 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK